Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that BRAF inhibitors, particularly Encorafenib and Dabrafenib, may have potential applications in wound healing by targeting specific proteins involved in the healing process in murine models.

This review covers the current status of the interstitial pneumonia with autoimmune features (IPAF) category, pointing out the need for revision of its criteria to establish it as a standalone diagnostic term, but reports no new clinical findings.

This study demonstrated that in live rodents, actin filaments adjust their structure to facilitate membrane transfer between cellular compartments with different biophysical properties.

This study found that microwave-assisted extraction significantly increased the yield of secondary metabolites, including phenolic and flavonoid content, from Nardostachys jatamansi, enhancing its anti-Alzheimer's potential compared to conventional extraction methods.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This study found that JAK1 and JAK3 inhibitors effectively reversed alopecia in a mouse model of AA by reducing skin inflammation, while JAK2 inhibition did not promote hair regrowth.

Farudodstat may effectively treat alopecia areata without harmful side effects.

This study identified neprilysin as a potential target of the pharmacological agent arteannuin, which may guide future research into its clinical applications, although experimental verification is needed.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.

This study suggests that the residues Val-889 and Arg-752 in the androgen receptor steroid binding domain are crucial for the intermolecular interaction necessary for receptor dimerization and function.

This study found that most pathogenic HR mutants associated with atrichia with papular lesions had abolished corepressor activity due to defective interactions with histone deacetylases.

This case report describes a patient who developed multiple skin reactions, including eczematous lesions and alopecia areata, during adalimumab treatment, but found no improvement in pustulosis palmoplantaris with different biologics.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This study found that early treatment of alopecia areata with JAK inhibitors can improve patients' physical and psychological quality of life without worsening skin lesions associated with sarcoidosis.

This study found that in Arabidopsis, root hair-specific proteins ADF8 and ADF11 are crucial for responding to hormonal signals like auxin and ethylene, which in turn modulate actin filament dynamics and are key for root hair growth under various environmental conditions.

In this study, the researchers used the dual-flow-RootChip to show that Arabidopsis roots can locally adapt their hair development in response to asymmetric phosphate conditions.

JAK inhibitors are generally safe for treating alopecia areata.

Abatacept may help some people with alopecia areata regrow hair.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

This article reviews the effectiveness of adrenal cortex compounds E and F in treating various connective tissue disorders and reports no new clinical findings.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

A new microneedle patch effectively and safely treats alopecia areata.

This genome-wide association study identified several genetic markers, including specific SNPs and HLA genotypes, associated with alopecia areata susceptibility in the Taiwanese population, highlighting key pathways involved in immune response and offering insights into the genetic origins of this autoimmune condition.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This study introduced a new adaptive microrhizotron for non-destructive observation of pepper root traits, finding that specific installation patterns significantly enhanced root interception probability while effectively measuring root architecture for plant research.

Hard α-keratin in hair has a unique, nonordered structure, different from other fibers.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.